Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation

European Journal of Immunology

Volumn 33, Issue 6, 2003, Pages 1508-1518

  Datta, Neeta ^a   Mukherjee, Snigdha ^a   Das, Lopamudra ^a   Das, Pijush K ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

CpG containing oligodeoxynucleotide; Cytokine; Leishmaniasis; Macrophage; Nitric oxide

Indexed keywords

CPG CONTAINING OLIGONUCLEOTIDE; CYTOKINE ANTIBODY; DNA; GAMMA INTERFERON; GAMMA INTERFERON ANTIBODY; IMMUNOSTIMULATING AGENT; INTERLEUKIN 12; INTERLEUKIN 4; LIPOSOME; MANNOSE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OLIGONUCLEOTIDE; UNCLASSIFIED DRUG;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CELL ENCAPSULATION; CELL SECRETION; CONTROLLED STUDY; DISEASE MODEL; EXPERIMENTAL DESIGN; EXPOSURE; IN VITRO STUDY; IN VIVO STUDY; LEISHMANIA DONOVANI; LYMPHOCYTE ACTIVATION; MACROPHAGE; MOUSE; NONHUMAN; PARASITE; PRIORITY JOURNAL; PROTEIN TARGETING; REINFECTION; SPLEEN CELL; SUPERNATANT; T LYMPHOCYTE; TH1 CELL; TH2 CELL; UPREGULATION; VISCERAL LEISHMANIASIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL; CPG ISLANDS; CRICETINAE; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; IMMUNITY, NATURAL; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-4; INTERLEUKINS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LIPOSOMES; LYMPHOCYTE ACTIVATION; MACROPHAGES, PERITONEAL; MANNOSE; MICE; MICE, INBRED BALB C; MODELS, ANIMAL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; OLIGODEOXYRIBONUCLEOTIDES; SPLEEN; T-LYMPHOCYTE SUBSETS; TH1 CELLS; TH2 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0038421089     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200323671     Document Type: Article

References (35)

1. Chance, M. L., New developments in the chemotherapy of leishmaniasis. Ann. Trop. Med. Parasitol. 1995. 89 (Suppl 1): 37-43.
2. Saha, B., Das, G., Vohra, H., Ganguly, N. K. and Mishra, G. C., Macrophage-T cell interaction in experimental visceral leishmaniasis: failure to express costimulatory molecules on Leishmania-infected macrophages and its implication in the suppression of cell-mediated immunity. Eur J. Immunol. 1995. 25: 2492-2498.
3. Kemp, M., Regulator and effector functions of T cell subsets in human Leishmania infections. APMIS Suppl. 1997. 68: 1-33.
4. Diefenbach, A., Schindler, H., Rollinghoff, M., Yokoyama, W. M. and Bogdan, C., Requirement for type 2 NO synthase for IL-12 signalling in innate immunity. Science 1999. 284: 951-955.
5. Engwerda, C. R., Murphy, M. L., Cotterell, S. E., Smelt, S. C. and Kaye, P. M., Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani. Eur. J. Immunol. 1998. 28: 669-680.
6. Alexander, J., Carter, K. C., Al-Fasi, N., Satoskar, A. and Brombacher, F., Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Eur. J. Immunol. 2000. 30: 2935-2943.
7. Lehmann, J., Enssle, K. H., Lehmann, I., Emmendorfer, A. and Lohmann-Matthes, M. L., The capacity to produce IFN-γ rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice. J. Interferon Cytokine Res. 2000. 20: 63-77
8. Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sat, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K. and Akira, S., A Toll-like receptor recognizes bacterial DNA. Nature 2000. 408: 740-745.
9. Klinman, D. M., Yi, A. K., Beaucage, S. L., Conover, J. and Krieg, A. M., CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon-γ. Proc. Natl. Acad. Sci. USA 1996. 93: 2879-2883.
10. Krieg, A. N., The role of CpG motifs in innate immunity. Curr. Opin. Immunol. 2000. 12: 35-43.
11. Chace, J. H., Hooker, N. A., Mildenstein, K. L., Krieg, A. M. and Cowdery, J. S., Bacterial DNA-induced NK cell IFN-γ production is dependent on macrophage secretion of IL-12. Clin. Immunol. Immunopathol. 1997. 84: 185-193.
12. Manetti, R., Parronchi, P., Giudizi, M. G., Piccinni, M. P., Maggi, E., Trinchieri, G. and Romagnani, S., Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J. Exp. Med. 1993. 177: 1199-1204.
13. Elkins, K. L., Rhinehart-Jones, T. R., Stibitz, S., Conover, J. S. and Klinman, D. M., Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J. Immunol. 1999. 162: 2291-2298.
14. Zimmerman, S., Egeter, O., Hausmann, S., Lipford, G. B., Rocken, M., Wagner, H. and Heeg, K., Cutting edge: CpG oligonucleotices trigger protective and curative Th1 responses in lethal murine leishmaniasis. J. Immunol. 1998. 160: 3627-3630.
15. Oxenius, A., Martinic, M. M. A., Hengartner, H. and Klenerman, P., CpG conlaining oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with T cell peptide vaccines. J. Virol. 1999. 73: 4120-4126.
16. Dow, S. W., Frandkin, L. G., Liggitt, D. H., Willson, A. P., Heath, T. D. and Potter, T. A., Lipid-DNA complexes induce potent activation of innate immunity responses and antitumor activity when administered intravenously. J. Immunol. 1999. 163: 1552-1561.
17. Barry, M. E., Pinto-Gonzalez, D., Orson, F. M., McKenzie, G. J., Petry, G. R. and Barry, M. A., Role of endogenous endonucleases and tissue site in transfection and CpG-mediated immune activation after naked DNA injection. Hum. Gene Ther. 1999. 10: 2461-2480.
18. Gursel, I., Gursel, M., Ishii, K. J. and Klinman, D. M., Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucliotides. J. Immunol. 2001. 167: 3324-3328.
19. Brandl, M., Liposomes as drug carriers: a technological approach. Biotechnol. Annu. Rev. 2001. 7: 59-85.
20. Stahl, P. D. and Ezekowitz, R. A. B., The mannose receptor is a pattern recognition receptor involved in host defense. Curr. Opin. Immunol. 1998. 10: 50-55.
21. Kole, L., Das, L. and Das, P. K., Synergistic effect of interferon-γ and mannosylated liposome-incorporated doxorubicin in the therapy of experimental visceral leishmaniasis. J. Infect. Dis. 1999. 180: 811-820.
22. Kedar, E., Palgi, O., Golod, G., Babai, I. and Barenholz, Y., Delivery of cytokines by liposomes. III. Liposome-encapsulated GM-CSF and TNF-alpha show improved pharmacokinetics and biological activity and reduced toxicity in mice. J. Immunother. 1997. 20: 180-193.
23. Chonn, A. and Cullis, P. R., Recent advances in liposomal drug-delivery systems. Curr. Opin. Biotechnol. 1995. 6: 698-708.
24. Gregoriadis, D., Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol. 1995. 13: 527-537.
25. Stahl, P. D., The macrophage mannose receptor: current status. Am. J. Respir. Cell. Mol. Biol. 1990. 2: 317-318.
26. Das, P. K., Murray, G. J., Gal, A. E. and Barranger, J. A., Glucocerebrosidase deficiency and lysosomal storage of glucocerebroside induced in cultured macrophages. Exp. Cell. Res. 1987. 168: 463-474.
27. Ahmad, I., Sarkar, A. K. and Bachhawat, B. K., Mannosylated liposome-mediated delivery of amphotericin B in the control of experimental aspergillosis in BALB/c mice. J. Clin. Biochem. Nutr. 1991. 10: 171-179.
28. Murray, H. W. and Nathan, C. F., Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J. Exp. Med. 1999. 189: 741-746.
29. + T cell responses in vivo. Blood. 2000. 96: 3505-3513.
30. Sarkar, K. and Das, P. K., Protective effect of neoglycoprotein-conjugated muramyl dipeptide against. Leishmania donovani infection: the role of cytokines. J. Immunol. 1997. 158: 5357-5365.
31. Hartmann, G., Weeratna, R. D., Ballas, Z. K., Payette, P., Blackwell, S., Suparto, I., Ramussen, W. L., Waldschmidt, M., Sajuthi, D., Purcell, R. H., Davis, H. L. and Krieg, A. M., Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J. Immunol. 2000. 164: 1617-1624.
32. Bachhawat, B. K., Das, P. K. and Ghosh, P., Preparation of glycoside-bearing liposomes for targeting. In Gregoriadis, G. (Ed.) Liposome Technology. Vol. III. CRC Press, Boca Raton 1984, pp 117-124.
33. Ding, A. H., Nathan, C. F. and Stuehr, D. J., Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production. J. Immunol. 1988. 141: 2407-2412.
34. Murray, H. W., Miralles, G. D., Stoeckle, M. Y. and McDermott, D. F., Role and effect of IL-12 in experimental visceral leishmaniasis. J. Immunol. 1993. 151: 929-938.
35. Kawakami, K., Tohyama, M., Qifeng, X. and Saito, A., Expression of cytokines and inducible nitric oxide synthase mRNA in the lungs of mice infected with Cryptococcus neoformans: effects of interleukin-12. Infect. Immun. 1997. 65: 1307-1312.